AbbVie Dividend Aristocrat Status

Описание: Video Chapters
00:00 Introduction: Assessing the Safety of AbbVie’s (ABBV) Dividend
00:15 The Humira Cliff: Managing Patent Expiry and Revenue Loss
00:39 The Safety Number: Net Income vs. Free Cash Flow Payout Ratios
01:08 Cash Flow Analysis: Why the 55% FCF Payout Ratio Matters
01:46 Dividend Sustainability: Post-Humira Cash Flow Trends
02:15 Pillar of Consistency: 53 Consecutive Years of Dividend Growth
02:56 Dividend Growth Evolution: Transitioning to a Sustainable Pace
03:36 Economic Stress Test: Dividend Resilience in 2008 and 2020
04:26 Final Verdict: Is ABBV a Rock-Solid Passive Income Stream?


📈 My Broker: Interactive Broker
Support the channel (no extra cost): ➡️ https://ibkr.com/referral/charles671

Is AbbVie's (ABBV) dividend a reliable cornerstone for a passive income portfolio? In this video, we dive deep into the numbers to see if this company can truly pay you for decades to come, especially after the loss of exclusivity for its blockbuster drug, Humira.

This deep dive into AbbVie's dividend focuses on the key metrics for long-term investors: the Free Cash Flow Payout Ratio, the history of dividend growth, its performance during recessions (the stress test), and the total shareholder yield. We analyze the safety, reliability, and future growth prospects of ABBV stock as a source of passive income. Learn how the company's new blockbuster drugs, Skyrizi and Rinvoq, are rebuilding its financial fortress and ensuring the dividend's safety. This analysis is perfect for anyone looking to build a rentier portfolio with high-quality, dividend-growing stocks.

About Our AI-Powered Process (Transparency Statement)
This entire analysis was generated by a custom AI system, guided and curated by a human strategist. Our goal is to leverage technology to provide deep, data-driven insights and a unique perspective on investing.

// EXPLORE OUR OTHER SERIES
• The MOAT Report
• Synaptic Dividends
• The Alpha Library
• The Alpha Mind
• Portfolio Blueprint

// DISCLAIMER
This video is for informational purposes only and does not constitute financial advice.